Marinomed Biotech AG Overview
Marinomed Biotech AG was an Austrian science-driven biopharmaceutical company built on two proprietary platforms: Carragelose, an iota-carrageenan red-algae polymer with virus-blocking, allergen-blocking and moisturising properties, commercialised as an over-the-counter portfolio of nasal sprays, throat products and eye drops through roughly 20 licensing partners worldwide; and Marinosolv, a patented solubilisation technology that brings poorly water-soluble drugs such as budesonide and tacrolimus into aqueous solution, enabling lower doses, faster onset and preservative-free formulations for sensitive tissues like the nose and eye. After a first court-supervised restructuring in 2024, the company sold its revenue-generating Carragelose business to French CDMO Unither Pharmaceuticals for up to EUR 20 million, pivoting to an asset-light licensing model around Marinosolv (Budesolv, Tacrosolv, Satiasolv) and Solv4U services. Non-receipt of Unither earn-outs triggered a second insolvency in July 2026, culminating in court-ordered dissolution in September 2026.
Company's own description (Annual Financial Report 2025)
In its FY2025 annual report, Marinomed describes itself as a biopharmaceutical company focused on the invention, development and licensing of drugs, having achieved milestones in respiratory, infectious, immune and eye diseases based on patented platforms. Its stated model is to concentrate on what it does best — identifying substances and indications, early and mid-stage drug development, medical device development and partnering — while leveraging larger pharmaceutical partners for late-stage clinical development, regulatory management and marketing. Revenue may be generated through product sales, patents, data, licensing or similar transactions. Partners typically take over the entire commercial value chain from manufacturing to distribution in exchange for upfront, milestone and royalty payments, allowing Marinomed to remain "asset-light."
The latest standard corporate boilerplate (July 2026) described Marinomed as an Austrian, science-based biotech company with a growing development pipeline that develops patent-protected products on the Marinosolv platform, which improves solubility and bioavailability of hardly soluble compounds for autoreactive immune disorders.
Independent characterisation
Marinomed was, in substance, a micro-cap European platform biotech that for most of its listed life financed R&D from a modestly profitable-at-gross-level OTC medical-device franchise (Carragelose), supplemented by EIB venture debt, convertible notes and small equity raises. The Carragelose franchise benefited from a pandemic-era demand spike (FY2021–FY2022 revenue of EUR 11.6m and EUR 11.3m respectively) but normalised in FY2023 (EUR 9.2m) and collapsed in FY2024 (EUR 4.7m) as partner ordering faltered and the company entered insolvency. The Marinosolv platform produced clinically validated assets — Budesolv met all endpoints in a Phase III trial for allergic rhinitis, and Tacrosolv showed Phase IIa efficacy — but late-detected room-temperature stability problems derailed partnering for years. From March 2025 onward, Marinomed had essentially no recurring product revenue, relied on a EUR 5m upfront from Unither, small service fees and successive dilutive micro-raises, and carried a fixed restructuring-quota repayment schedule it could only meet if contingent earn-outs materialised. They did not, and the company failed.
Business model and revenue model mix
| Revenue stream | Description | Status at dissolution |
|---|---|---|
| Product sales (Carragelose OTC) | Supply of finished Carragelose nasal sprays, lozenges and eye drops to ~20 licensees/distributors | Divested to Unither (closed 28 Feb 2025); remaining stock sold to Unither |
| Licensing / milestones (Carragelose) | Licence fees and milestones from regional partners (e.g., Procter & Gamble for US) | Transferred to Unither with all contracts |
| Licensing / milestones (Marinosolv products) | Upfront/milestone/royalty deals for Budesolv (Luoxin – Greater China; Swiss partner), Tacrosolv (none closed) | Assets to be sold by administrator |
| Solv4U technology services | Fee-for-service feasibility and formulation studies; follow-on licences (Aché – Brazil, SPH Sine – China, Unither – France) | Ceased with operations |
| Pharmaceutical services | Virological, immunological, toxicological assays; ex-vivo models (fee-for-service) | Ceased |
| Transition service agreement | Regulatory, BD and R&D services to Unither post-closing | Ceased |
| Compounding (announced Apr 2026) | Marinosolv-based solutions for compounding pharmacies; first revenues targeted Q4 2026/early 2027 | Never generated revenue |
| Disposal proceeds / earn-out | EUR 5m fixed price received; up to EUR 15m earn-out contingent until mid-2027 | Earn-out disputed, not received |
Quantified mix by stream is not publicly disclosed for FY2025 beyond the statement that EUR 5.0m of EUR 7.7m revenue was the Unither upfront and the remainder comprised delayed 2024 orders, inventory sale to Unither, other Carragelose-sale proceeds and Solv4U research revenue (Annual Financial Report 2025).
Value-chain position, customers and end markets
Marinomed sat in early-to-mid-stage drug and device R&D, outsourcing manufacturing (fill-finish via CMOs) and commercialisation. Customer types: (i) OTC pharmaceutical marketers and distributors (Carragelose era); (ii) mid-sized and large pharma licensees for Rx assets (Luoxin, Swiss partner, Phargentis); (iii) pharma/biotech formulation clients (Solv4U); (iv) planned compounding pharmacies. End markets: cough, cold and allergy consumer healthcare; allergic rhinitis Rx; ophthalmology (dry eye, inflammatory ocular surface disease, vernal keratoconjunctivitis); drug-delivery/bioavailability enhancement; respiratory inhalation (via Phargentis).
Strategy
Stated strategy (Annual Financial Report 2025, paraphrased themes)
Management characterised the 2024–2025 restructuring as an opportunity: it produced a EUR 18.9m restructuring gain, converted remaining unsecured liabilities into interest-free tranches, and — after scheduled repayments — would leave the company debt-free from mid-2027 except for real-estate financing and the two convertible bonds. The overarching goal was sustainable profitability, with an explicit aim of profitability from 2025 onward. The strategy shifted the revenue model from merchandise sales to licensing deals with upfront and milestone payments, complemented by earn-outs, the Unither service agreement and Solv4U services.
Four key projects (AR 2025)
| # | Project | Objective | Outcome by Oct 2026 |
|---|---|---|---|
| a | Maximise Carragelose earn-out | Support Unither integration (P&G US certification; eye-drop rollout) to unlock up to EUR 15m by mid-2027 | Failed: no earn-out received; Unither terminated negotiations; Marinomed alleged culpable delays and strategy change by Unither |
| b | Budesolv licences and first approval | Complete MAA data; file first in Switzerland; sign further partners | Swiss term sheet only; MAA filing (targeted Q1 2026 per First Berlin) not confirmed |
| c | First Tacrosolv partnership | Leverage reformulation and packaging; ride interest after Novaliq/Théa deal | No partnership announced |
| d | Expand Solv4U and services | Grow beyond feasibility studies; Satiasolv data; pharma services | Phargentis inhalation term sheet (May 2026); compounding entry (Apr 2026); no material revenue before closure |
Initiatives announced in the last 24 months
| Date | Initiative | Type | Targets / terms |
|---|---|---|---|
| Nov 2024 | Carragelose divestiture to Unither | Portfolio transformation | Up to EUR 20m (EUR 5m fixed + up to EUR 15m earn-out) |
| Nov 2024 | Restructuring plan | Financial restructuring | 30% quota (EUR 8.0m) to May 2027; up to 37% if earn-out exceeds plan |
| 2,025 | Cost reduction | Cost programme | FTE down from 42 to 32; external research and patent costs cut |
| Jun 2025 | Budesolv Swiss partnership | Licensing | Exclusive Swiss (and Austrian per German release) rights; milestones + royalties |
| Sep 2025 | Capital increase + EUR 2.5m convertible | Financing | EUR 1.08m at EUR 17.50; CB conversion at EUR 15 |
| Mar–Apr 2026 | Rights issue | Financing | Up to 459,985 shares at EUR 14; EUR 2.23m net raised |
| Apr 2026 | Compounding services | New business | First revenue Q4 2026/early 2027 |
| May 2026 | Phargentis inhalation licence | Platform licensing | Fee-for-service, milestones, royalties |
| Jul 2026 | Second restructuring and legal action vs Unither | Restructuring / litigation intent | New restructuring plan; legal remedies against Unither |
Medium-term guidance
In March 2026, the CEO stated that the business plan projected profits for 2026 and subsequent years, driven by marketing of Budesolv and Tacrosolv. In a GBC AG interview (October 2025), management described a five-year vision of a profitable company with steadily rising Budesolv licence income. First Berlin (June 2025) modelled EBITDA of EUR 3.0m (2026E), EUR 3.3m (2027E) and EUR 3.3m (2028E), with equity turning positive in 2028E. All guidance has been superseded by the dissolution. ESG/sustainability commitments: no quantified targets disclosed.
Products & Services
Virology segment — Carragelose (divested Feb 2025)
| Product line | Description | Key capabilities | Target customer | Status / year | Pricing model |
|---|---|---|---|---|---|
| Carragelose virus-blocking nasal sprays | Iota-carrageenan nasal spray forming a protective gel layer on mucosa | Broad-spectrum physical virus blocking; clinical data incl. SARS-CoV-2 inhibition | OTC consumers via pharma partners | Marketed since late 2000s; transferred to Unither 2025 | Supply price + licence fees (partner-specific, not disclosed) |
| Carragelose throat products | Throat sprays / lozenges | Same mechanism for oropharynx | OTC consumers | Transferred 2025 | — |
| Carragelose allergy / allergen-blocking products | Nasal products blocking allergens | Allergen barrier; launched in Austria and Mexico | Allergy sufferers | Launched 2023–2024 (per roic.ai summary); transferred 2025 | — |
| Carragelose eye drops | Moisturising dry-eye drops | Lubrication/protection | Dry-eye OTC market | Launched in Austria by Sigmapharm H1 2025 (temporarily out of stock due to demand) | — |
| US Carragelose (P&G) | Nasal spray under Procter & Gamble for US market | US certification in progress | US OTC | Agreement 2022; US approval pending at FY2025 report | — |
Immunology segment — Marinosolv proprietary candidates
| Candidate | Active ingredient | Indication | Phase (latest) | Key data / specs | Partnering |
|---|---|---|---|---|---|
| MAM-1004-1 / Budesolv | Budesonide (solubilised) | Severe allergic rhinitis | Filing in preparation (Swiss MAA targeted) | Met all Phase III endpoints; ~85% lower dose than comparable marketed products; reduction of nasal and asthmatic symptoms within three hours of first dose; no shaking; preservative-free; reformulated for stability with new patent protecting IP to 2043 | Luoxin (Greater China, 2021, USD 2m upfront); Swiss partner (2025, milestones + royalties) |
| MAM-1003-1 / Tacrosolv | Tacrolimus (solubilised) | Severe inflammatory ocular surface disease (model: allergic rhinoconjunctivitis; target incl. VKC) | Phase II | Phase IIa: higher dose relieved eye and nose allergy symptoms after eight days; higher ocular tissue levels than Talymus suspension despite 95% lower concentration; reformulated with new primary packaging | No partner closed; interest reportedly increased after Novaliq–Théa CyclASol deal |
| MAM-1018-1 / Satiasolv | Cannabidiol (solubilised) | Pain / immune reactions | Preclinical | Oral preclinical model: significantly more efficient brain uptake vs oil-based comparator | Marketed via Solv4U |
| Phargentis inhalation formulation | Combination of APIs | Respiratory (inhalation) | Formulation development | Term sheet 19 May 2026; worldwide exclusive Marinosolv licence | Phargentis SA — fee-for-service, milestones, royalties |
| Tacrolimus eye drops for compounding | Tacrolimus | Compounding market | Pre-launch | Progress announced 2026 (MarketScreener headline) | Planned compounding channel |
Others segment — Solv4U and services
| Offering | Description | Launch | Revenue model | Named clients |
|---|---|---|---|---|
| Solv4U feasibility studies | Demonstrate Marinosolv solubilisation of client APIs | Nov 2021 | Fee-for-service | Multiple (not all disclosed) |
| Solv4U formulation optimisation & licensing | Follow-on development and licence | 2023 onward | Milestones + licence fees | Aché (Brazil), SPH Sine (China), Unither (France) |
| Pharmaceutical assays | Virological, immunological, toxicological assays | 2,024 | Fee-for-service | — |
| Ex-vivo models | Tissue models for external customers | 2,025 | Fee-for-service | — |
| Compounding solutions | Marinosolv-enabled formulations for compounding pharmacies | Announced 22 Apr 2026; revenue expected Q4 2026/early 2027 | Product/solution supply | None (ceased before launch) |
Platform technology — Marinosolv specification summary
Per the FY2025 annual report, Marinosolv is a set of excipients that solubilises small hydrophobic molecules and peptides for liquid and semi-solid dosage forms. Claimed advantages: clinical validation; broad applicability; tolerability on eyes and nose; faster onset than suspensions; significantly lower dose with potential side-effect reduction; higher target-tissue bioavailability; possibility of sterile filtration and preservative-free formulations; reduced environmental API burden; scalable process.
Financial Narrative
Basis: FY2021–FY2023 figures from company press releases and aggregators (consolidated/UGB as reported at the time); FY2024–FY2025 from the Annual Financial Report 2025 (UGB single entity). "n/d" = not publicly disclosed or not verifiable from retrieved sources. Derived figures are labelled.
Income statement
Notes: EBITDA FY2021–FY2024 derived from reported EBITDA margins (boersengefluester.de: -30.44%, -37.59%, -48.48%, -137.68%) applied to revenue; First Berlin (June 2025) shows FY2023 EBITDA of EUR -4.52m to -4.54m and FY2024 of EUR -6.54m to -6.55m, consistent. FY2025 EBITDA derived as operating result EUR 18.67m plus D&A EUR 0.31m. FY2025 EPS from Investing.com (basic) and Yahoo Finance (diluted) — aggregator figures. FY2021–FY2022 EPS from FY2022 results release. FY2022 revenue derived from company statement that revenue rose 16.5% excluding the EUR 1.9m 2021 milestone (EUR 9.7m × 1.165 ≈ EUR 11.3m), consistent with net-margin data.
Margins
Revenue CAGR FY2021–FY2025: (7.7 / 11.6)^(1/4) − 1 = −9.7% p.a. FY2025 margins are meaningless as operating indicators: they are driven by the EUR 18.9m non-cash restructuring gain and the EUR 5.0m one-off disposal upfront recognised in revenue.
Commentary. The income statement tells a three-act story. Act one (FY2021–FY2022) shows a pandemic-boosted Carragelose franchise at EUR 11–12m revenue with persistent EUR 6m net losses funded by the IPO and EIB loan, as R&D (approximately EUR 7.5m in FY2021 per company release) outstripped gross profit. Act two (FY2023–FY2024) is the unwind: post-pandemic normalisation cut revenue 19% in FY2023; in FY2024 partner orders and revenue expectations failed, and the company entered insolvency with a EUR 15.4m net loss inflated by EUR 6.7m of extraordinary expenses from termination of the EIB agreements (EIB claim rose from the EUR 15m principal to EUR 24.1m on early termination) and a EUR 0.65m impairment on the office building. Act three (FY2025) is an accounting profit of EUR 18.0m that masks an underlying operating loss: stripping out the EUR 18.9m restructuring gain and the EUR 5.0m Unither upfront, adjusted operating result was roughly EUR −5.2m, comparable to prior years on a far smaller revenue base. Personnel costs fell 17% (42 to 32 FTE) and purchased services fell from EUR 1.1m to EUR 0.2m, but other operating expenses stayed flat at EUR 2.75m because of the cyber-fraud loss and deal advisory costs.
Balance sheet
Sources: AR 2025 balance sheet (FY2024–FY2025); cash FY2021 per Q1 2022 PR (EUR 5.8m at 31 Dec 2021); cash FY2022 and FY2023 and equity FY2023 per First Berlin (June 2025) model (EUR 8.12m opening 2023 cash; EUR 2.56m closing 2023; equity EUR −11.5m); FY2022 equity EUR −4.15m per boerse-express aggregator (year mapping uncertain, flagged). Note discrepancy: First Berlin shows FY2024 equity of EUR −25.0m versus EUR −26.2m in the audited UGB single-entity statement; the audited figure is used.
FY2025 liability detail (AR 2025): bank liabilities EUR 8.37m (EUR 2.78m due within one year; EUR 5.59m beyond), convertible bonds EUR 3.04m (EUR 2.56m within one year), trade payables EUR 0.16m, other liabilities EUR 0.58m, accruals EUR 0.63m. Bank liabilities include restructuring-quota obligations to the EIB and real-estate loans of approximately EUR 4.0m secured on the Korneuburg HQ (ERP loan rate raised to 8.5% after insolvency). By July 2026, total liabilities had risen to approximately EUR 27.9m, including 2024 claims that became enforceable again once the restructuring plan could not be fulfilled (EQS, 22 July 2026).
Commentary. Marinomed carried negative equity from at least FY2022, legally tolerated under Austrian insolvency law only because management maintained a positive going-concern forecast. The 2025 restructuring compressed debt from EUR 28.2m to EUR 11.4m, but cash of EUR 1.0m against EUR 6.1m of liabilities due within twelve months (current ratio ≈0.24) left the company entirely dependent on contingent inflows. The auditor's "material uncertainty related to going concern" framing in the FY2025 notes explicitly assumed substantial but unsecured payments in Q2 and Q3 2026 — payments that did not arrive.
Cash flow
Sources: AR 2025 (FY2024–FY2025); First Berlin June 2025 (FY2023). Note: H1 2025 operating cash flow was EUR −0.2m and Q1 2025 was positive EUR +2.9m owing to the Unither upfront; the FY2025 annual operating cash flow of EUR −1.1m implies the EUR 5m was largely consumed by quota payments (classified as operating/financing outflows) and running costs. First Berlin had forecast positive operating cash flow of EUR 3.0m for 2025E; actual was negative.
Ratios
ROE and debt/equity are not meaningful given negative equity in every year with data. FY2025 ROA, net debt/EBITDA and interest coverage are distorted by the restructuring gain and should not be interpreted as indicators of operating health. Cash conversion cycle is not computable after inventory fell to near zero in FY2025 (EUR 1.1k).
Interim data points (2025–2026)
Sources: Q1 2025 and H1 2025 results releases. H1 2026 report (scheduled 16 Sep 2026) was postponed indefinitely and never published.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Segment Overview
| Segment | Contents | Products / services | Status |
|---|---|---|---|
Virology | Carragelose platform | Carragelose nasal sprays (virus-blocking, allergy, moisturising), throat sprays/lozenges, eye drops; licences to ~20 partners | Divested to Unither, closed 28 Feb 2025 |
Immunology | Proprietary Marinosolv drug candidates | Budesolv (MAM-1004-1), Tacrosolv (MAM-1003-1); Satiasolv (MAM-1018-1) referenced under Solv4U marketing | Assets in insolvency estate |
Others | Solv4U unit | Formulation feasibility/optimisation studies, licences, pharmaceutical assays, ex-vivo models | Ceased |
Segment revenue (EUR Mn)
| Segment revenue (EUR Mn) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Virology (Carragelose) revenue | 9.7 | 11.2 | — | — | — |
Immunology (Marinosolv milestones) revenue | 1.9 | 0.0 | — | — | — |
Unither upfront (recognised as revenue) | 0.0 | 0.0 | 0.0 | 0.0 | 5.0 |
Total revenue | 11.6 | 11.3 | 9.2 | 4.7 | 7.7 |
Group Entities
| Entity | Relationship | Status |
|---|---|---|
Marinomed Biotech AG | Parent / sole operating entity | Dissolved Sep 2026; in liquidation |
Marino Immo GmbH | Former 100% property subsidiary | Sold by notarial deed 19 Dec 2024; disposal effective Jan 2025 |
Branches | None (per AR 2025) | — |
Income Statement and Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue (EUR Mn) | 11.6 | 11.3 | 9.2 | 4.7 | 7.7 |
Revenue YoY growth (%) | — | -2.6 | -18.6 | -48.4 | 62.0 |
Other operating income (EUR Mn) | — | — | — | 0.1 | 19.5 |
Cost of materials and purchased services (EUR Mn) | — | — | — | 3.8 | 1.4 |
Gross profit, revenue less materials/services (EUR Mn, derived) | — | — | — | 1.0 | 6.3 |
Personnel expenses (EUR Mn) | — | — | — | 4.8 | 4.0 |
Other operating expenses (EUR Mn) | — | — | — | 2.8 | 2.8 |
EBITDA (EUR Mn, derived) | -3.5 | -4.3 | -4.5 | -6.5 | 19.0 |
Depreciation and amortisation (EUR Mn) | — | — | — | 1.1 | 0.3 |
Operating result / EBIT (EUR Mn) | — | — | — | -7.6 | 18.7 |
Financial result (EUR Mn) | — | — | — | -7.9 | -0.5 |
Pre-tax income (EUR Mn) | — | — | — | -15.5 | 18.1 |
Net income (EUR Mn) | -5.9 | -6.4 | -6.8 | -15.4 | 18.0 |
EPS basic (EUR) | -4.0 | -4.3 | — | — | 9.79 |
EPS diluted (EUR) | — | — | — | — | 9.76 |
Dividend per share (EUR) | 0 | 0 | 0 | 0 | 0 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansMargin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Gross margin, revenue less materials/services (%) | — | — | — | 20.3 | 81.7 |
EBITDA margin (%) | -30.4 | -37.6 | -48.5 | -137.7 | 246.8 |
Operating (EBIT) margin (%) | — | — | — | -160.1 | 242.7 |
Net margin (%) | -50.7 | -56.7 | -74.1 | -324.6 | 234.3 |
Balance Sheet
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Total assets (EUR Mn) | — | — | — | 8.2 | 6.0 |
Cash and equivalents (EUR Mn) | 5.8 | 8.1 | 2.6 | 1.7 | 1.0 |
Intangible assets (EUR Mn) | — | — | — | 0.09 | 0.01 |
Goodwill (EUR Mn) | 0 | 0 | 0 | 0 | 0 |
Land and buildings (EUR Mn) | — | — | — | 4.4 | 4.2 |
Short-term financial debt incl. convertibles (EUR Mn) | — | — | — | 28.2 | 5.3 |
Long-term financial debt incl. convertibles (EUR Mn) | — | — | — | 0.0 | 6.1 |
Total financial debt (EUR Mn) | — | — | — | 28.2 | 11.4 |
Net debt (EUR Mn) | — | — | — | 26.5 | 10.5 |
Shareholders' equity (EUR Mn) | — | -4.2 | -11.5 | -26.2 | -7.0 |
Working capital, current assets less current liabilities and accruals (EUR Mn, derived) | — | — | — | -30.9 | -5.3 |
Cash Flow
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Operating cash flow (EUR Mn) | — | — | -3.7 | -2.4 | -1.1 |
Capex / investing cash flow (EUR Mn) | — | — | — | -0.1 | 0.0 |
Free cash flow (EUR Mn, derived) | — | — | — | -2.5 | -1.1 |
Financing cash flow (EUR Mn) | — | — | -1.7 | 1.6 | 0.3 |
Net change in cash (EUR Mn) | — | — | -5.6 | -0.9 | -0.8 |
Dividends paid (EUR Mn) | 0 | 0 | 0 | 0 | 0 |
Share buybacks (EUR Mn) | 0 | 0 | 0 | 0 | 0 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2024 | FY2025 |
|---|---|---|
ROA, net income / average total assets (%) | — | 255 |
Current ratio (x) | 0.10 | 0.24 |
Net debt / EBITDA (x) | — | 0.55 |
Interest coverage, EBIT / interest expense (x) | -0.96 | 34.4 |
Asset turnover, revenue / average assets (x) | — | 1.09 |
Income Statement
| Metric | Q1 2024 | Q1 2025 | H1 2024 | H1 2025 |
|---|---|---|---|---|
Revenue (EUR Mn) | 0.74 | 6.53 | 2.42 | 7.18 |
Operating result / EBIT (EUR Mn) | -1.86 | 22.22 | -3.18 | 20.97 |
Net result (EUR Mn) | -2.18 | 22.12 | — | — |
R&D expenses (EUR Mn) | — | — | 2.39 | 1.40 |
Cash at period end (EUR Mn) | 1.71 | 4.57 | 0.9 | 1.5 |
Region revenue (EUR Mn)
| Region revenue (EUR Mn) | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Total revenue | 9.2 | 4.7 | 7.7 |
Valuation Snapshot
| Metric | Value | Basis |
|---|---|---|
Last price | EUR 4.00 (17 Oct 2026) | Investing.com |
IPO price | EUR 75.00 (1 Feb 2019) | AR 2025 |
Return since IPO | −94.7% | Derived |
1-year change | approx. −80% | Investing.com |
YTD 2026 change | approx. −77% (as of 28 Aug 2026 at EUR 4.40) | MarketScreener |
52-week high / low | EUR 21.00 / EUR 2.20 | comdirect / Investing.com |
3-year and 5-year returns | Not reliably retrievable; 5-year return deeply negative (IPO-era prices ~EUR 75) | — |
Trading regime | Auction trading on Vienna Stock Exchange since Aug 2026 (market maker RBI withdrew 22 Jul 2026) | börse-global; EQS |
Average volume (3m) | approx. 1,450 shares/day | Investing.com |
Share Price
| Metric | IPO Feb 2019 | Q2 2025 peak | Sep 2025 placement | Mar 2026 rights issue | Aug 2026 | Oct 2026 |
|---|---|---|---|---|---|---|
Price or issue price (EUR) | 75.00 | 20.00 | 17.50 | 14.00 | 5.40 | 4.00 |
Share Price & Returns
| Date | Instrument | Shares / nominal | Price (EUR) | Gross proceeds (EUR Mn) |
|---|---|---|---|---|
Sep 2024 | Cash capital increase (no subscription rights) | 154,053 | 5.00 | 0.77 |
Dec 2024 | Private placement | 83,750 | 8.00 | 0.67 |
Jan 2025 | EIB convertible | 84,768 conversion shares | 5.00 conv. | 0.42 nominal |
Sep 2025 | Cash capital increase (nine investors) | 61,607 | 17.50 | 1.08 |
Q4 2025 | Convertible bond | 166,666 conversion shares | 15.00 conv. | 2.50 |
Apr 2026 | Rights issue | 159,039 (of up to 459,985) | 14.00 | 2.23 net |
Valuation Multiples
| Multiple | Marinomed | Comment |
|---|---|---|
Market cap | EUR 8.0m | 1,998,979 shares |
Enterprise value (approx.) | EUR 18.4m | Market cap + FY2025 financial debt EUR 11.4m − cash EUR 0.95m; July 2026 liabilities of EUR 27.9m imply higher EV |
P/E (TTM) | ~0.4x | Meaningless: restructuring gain |
EV/EBITDA (FY2025) | ~1.0x | Meaningless: restructuring gain |
EV/Sales (FY2025) | ~2.4x | One-off revenue |
P/B | n/m | Negative equity |
Analyst Ratings & Targets
| Broker | Last action | Date | Rating / target |
|---|---|---|---|
First Berlin Equity Research (Alexander Rihane) | Rating and target moved to Under Review | 20 Jul 2026 | Under Review (previously Buy; initiated 30 Jun 2025) |
GBC AG | Buy | 1 Oct 2025 | Buy; target horizon 31 Dec 2026 (target value n/d) |
MarketScreener consensus | P/E 2026E 3.55x; 2027E 3.01x (stale, pre-insolvency) | Aug 2026 | — |
Margin Analysis (%) (Nov 2025–Beyond 2027)
| Obligation | Nov 2025 | May 2026 | Nov 2026 | May 2027 | Beyond 2027 |
|---|---|---|---|---|---|
EIB quota payments (% of claim) | 5 | 5 | 5 | 10 | 0 |
Other creditors quota payments (% of claim) | 5 | 5 | 10 | 0 | 0 |
Analyst Conclusions
Management guidance
The last management guidance (March–May 2026) projected profits for 2026 and later years from Budesolv and Tacrosolv marketing, first compounding revenue in Q4 2026/early 2027, and debt-freedom (ex-property and convertibles) from mid-2027. All guidance is void following the court-ordered dissolution on 24 September 2026. No consensus growth expectations remain valid.
Bull-case arguments (residual — relevant to asset value and creditor recovery, not equity)
-
Unither claim may have value: Up to EUR 15m in contractual earn-outs remains disputed; if the administrator litigates successfully, recoveries could materially exceed the estate's other assets.
-
Marinosolv assets are clinically de-risked: A Phase III-positive Budesolv with IP to 2043 and a Phase II Tacrosolv could attract a buyer in an administrator-led sale, especially given demonstrated partner interest (Luoxin, Swiss partner, Phargentis).
-
Tangible real estate: Korneuburg land and buildings carried at EUR 4.2m provide hard-asset recovery for secured lenders.
Bear-case arguments
-
Equity likely worthless: Liabilities of ~EUR 27.9m versus total assets of ~EUR 6.0m at end-2025 imply shareholders rank behind a large creditor shortfall.
-
Distressed-sale discount: Assets with unresolved stability/regulatory histories and no team (operations ceased) typically sell at deep discounts in liquidation.
-
Litigation uncertainty and cost: The Unither earn-out depends on proving culpable delay; an insolvency estate may lack resources to pursue protracted cross-border litigation.
Catalysts and monitorables (next 12 months)
| Monitorable | Why it matters |
|---|---|
| Administrator's asset-sale process (Marinosolv IP, Budesolv, Tacrosolv, Satiasolv, real estate) | Determines creditor recovery |
| Any legal action or settlement with Unither | Largest potential recovery source |
| Insolvency quota announcements | Recovery for EIB and unsecured creditors |
| Delisting decision by Vienna Stock Exchange / FMA | End of equity trading |
| Fate of Luoxin, Swiss and Phargentis contracts | Transferability to acquirer |
| Treatment of convertible bonds and EIB claims | Ranking in liquidation |
| Publication (if any) of H1 2026 financials or administrator reports | Transparency on estate value |
Analyst verdict
Marinomed Biotech AG is a cautionary case study in how a scientifically credible platform company can fail on balance-sheet architecture rather than science. The Marinosolv technology generated genuinely differentiated clinical data — a Phase III win for Budesolv at a fraction of the incumbent dose, and encouraging Phase IIa results for Tacrosolv — yet the company never assembled the capital or the partner leverage to convert that data into approvals. Two compounding errors proved fatal. First, room-temperature stability problems surfaced only after pivotal development, resetting regulatory and partnering timelines by years. Second, the 2024 restructuring was engineered around contingent consideration: the creditor plan's 30% quota relied on up to EUR 15m of Unither earn-outs that Marinomed did not control, while the only certain consideration, EUR 5m, was quickly absorbed by quota payments, running costs and a EUR 677k cyber-fraud loss. The FY2025 accounting profit of EUR 18.0m was almost entirely a non-cash restructuring gain; adjusted for that and the one-off Unither upfront, the business was still burning roughly EUR 5m a year with under EUR 1m of cash. Successive micro-raises at falling prices (EUR 17.50 in September 2025, EUR 14 in March 2026 with only about a third of the offer taken up) signalled exhausted investor support well before the July 2026 filing. With the company dissolved by the Korneuburg insolvency court on 24 September 2026 and operations ceased, the listed equity should be regarded as having negligible expected value; any residual worth accrues first to secured lenders (Korneuburg property), the EIB and unsecured creditors. The only meaningful upside variable is the administrator's pursuit of the Unither earn-out claim and the price achievable for the Marinosolv IP estate. For investors, the verdict is unequivocal: avoid the equity; for strategic buyers, the Budesolv and Tacrosolv assets may represent an inexpensive option on validated solubilisation technology.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Tenure | Background | Compensation (latest) |
|---|---|---|---|---|
Dipl.-Ing. Dr. Andreas Grassauer | CEO, co-founder | Founder 2006; management board representative since 2 Jun 2017 | Co-founder from the University of Veterinary Medicine Vienna spin-off; long-time CEO through IPO, two insolvencies | Not publicly disclosed in retrieved sources |
Mag. Dr. Eva Prieschl-Grassauer | CSO, co-founder | Founder 2006; representative since 2 Jun 2017 | Scientific lead on Carragelose and Marinosolv | Not publicly disclosed in retrieved sources |
Pascal Schmidt | CFO (former) | Until 31 Jan 2025 | Led finance through IPO-era capital markets activity and 2024 restructuring | — |
“—” = not publicly disclosed.
Board of Directors
| Name | Role | Notes |
|---|---|---|
Dr. Simon Nebel, MBA | Chairman | Registered 2 Jun 2017; chair through 2025 |
Mag. Brigitte Ederer | Member | Listed in register extracts |
Dr. Elisabeth Lackner | Member | Elected at June 2022 AGM |
Dr. Karl Mahler | Member | Listed in register extracts |
Dr. Eva Hofstädter-Thalmann | Member (from 2023) | Elected 2023; global pharma expert |
Ulrich Kinzel | Member (from 2022) | Elected June 2022 |
Board & Management Changes
| Date | Change | Context |
|---|---|---|
31 Jan 2025 | CFO Pascal Schmidt departs | Immediately after end of first restructuring |
Feb 2025 | Supervisory board composition changes (register filings) | Post-restructuring governance reset |
Late Jul 2026 | Administrator Dr. Ulla Reisch appointed; management loses control (proceedings without self-administration) | Second insolvency |
24 Sep 2026 | Company dissolved; administrator assumes liquidation | Wind-up motion granted |
Major Shareholders
| Holder | Stake (%) | Type |
|---|---|---|
Andreas Grassauer (CEO) | 6.6 | Founder / insider |
Eva Prieschl-Grassauer (CSO) | 6.6 | Founder / insider |
Hermann Unger | 6.2 | Co-founder |
Abdulmohsen Al Sheikh | 3.5 | Former Acropora investor (stake split from Acropora) |
Mohammed Al Sheikh | 3.5 | Former Acropora investor |
Free float | 73.7 | Retail / institutional |
Competitive Landscape
Competitors by Segment
| Segment | Competitor | Relevance | Comparative scale |
|---|---|---|---|
Solubilisation / ophthalmic formulation | Novaliq GmbH (EyeSol; CyclASol, partnered with Théa) | Direct: water-free/solubilised ocular formulations; Marinomed's AR named it as benchmark for Tacrosolv | Private; revenue n/d |
Ophthalmic cyclosporine | Harrow (VEVYE, cyclosporine eye drops approved by FDA May 2023) | Competes with Tacrosolv in dry eye / ocular inflammation | — |
Ophthalmic immunomodulators | Sun Pharma (Cequa), Santen, Bausch + Lomb | Established dry-eye and ocular inflammation franchises | — |
Allergic rhinitis Rx/OTC corticosteroids | GSK/Haleon (fluticasone), Sanofi/Opella (triamcinolone OTC), Viatris (azelastine/fluticasone combo), Glenmark (olopatadine/mometasone) | Incumbent suspensions Budesolv aimed to displace | — |
Budesonide nasal | AstraZeneca/OTC licensees (budesonide nasal sprays) | Same molecule in suspension | — |
Bioavailability-enhancement CDMOs | Lonza, Catalent, Ascendia, Particle Sciences-type specialists | Compete with Solv4U for formulation services | — |
Compounding | Fagron and national compounding suppliers | Compete with planned compounding business | — |
Carragelose (legacy, now Unither) | Iota-carrageenan and barrier sprays from other OTC players | Competition now borne by Unither | Unither: EUR 475m sales (2023) |
Peer Comparison FY2025
| Metric | Marinomed (FY2025) | Unither Pharmaceuticals | Novaliq | Harrow |
|---|---|---|---|---|
Revenue | EUR 7.7m | EUR 475m (2023) | n/d (private) | n/d in this research |
Revenue growth | +62% (one-off driven) | — | — | — |
Operating margin | n/m (restructuring gain) | — | — | — |
R&D intensity | 34% of revenue | — | — | — |
Ownership | Listed, dissolved | Private | Private | Listed (Nasdaq) |



